悪性中皮腫治療薬の日本市場:市場インサイト、疫学分析、市場予測

【英語タイトル】Malignant Mesothelioma - Market Insights, Epidemiology and Market Forecast – 2023 - Japan

DelveInsightが出版した調査資料(DLVE704009)・商品コード:DLVE704009
・発行会社(調査会社):DelveInsight
・発行日:2017年1月
・ページ数:88
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後2営業日以内)
・調査対象地域:日本
・産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名使用)USD1,750 ⇒換算¥190,750見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD3,500 ⇒換算¥381,500見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD5,250 ⇒換算¥572,250見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

DelveInsight’s “Malignant Mesothelioma – Market Insights, Epidemiology and Market Forecast – 2023 – Japan” Reports provides an overview of the disease and global market size of the Malignant Mesothelioma for the Japan. It also includes global historical and forecasted epidemiological data for the diagnosed prevalent cases of Malignant Mesothelioma from 2010-2023. According to Publisher, the forecasted patient population of Malignant Mesothelioma will increase at a CAGR of XX% from 2010 to 2023 and the worldwide Malignant Mesothelioma market is estimated to be USD XX Million by 2023.Malignant mesothelioma is a deadly and rare form of cancer that affects the thin lining known as the mesothelium. Mesothelioma helps to protect the organs by making a special lubricating fluid that allows organs to move against each other. Malignant mesothelioma is a rare, asbestos-related cancer that forms on the thin protective tissues that cover the lungs and abdomen. It is a deadly disease as its prognosis is poor and the survival time after diagnosis is around 9-12 months.
Based on the organ which is first affected, mesothelioma can be divided into several categories-
•Pleural Mesothelioma: It affects lining of lungs. It is the most common type of mesothelioma and is caused by the inhalation of asbestos fibers. About 70% of the mesothelioma cases fall under this category.
•Peritoneal Mesothelioma: It affects the lining of abdomen. About 15-20 % cases of mesothelioma are diagnosed as peritoneal.
•Pericardial Mesothelioma: It affects the lining of heart. Asbestos fibers can get lodged in the pericardium which is the lining around the heart cavity. It’s a rare kind of mesothelioma which occurs in 1 % or less number of cases.
•Tunic vaginalis: It affects the testicles. This is also a rare kind of mesothelioma.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

Scope
- Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
- Marketed information including available prescription drugs, its patent and exclusivity details.
- It also provides Market size of Malignant Mesothelioma for Japan from 2010 and forecasted Market size to 2023.

【レポートの目次】

Report Introduction
Malignant Mesothelioma Market Overview at a Glance
Global Market Size of Malignant Mesothelioma in 2015
Global Market Size of Malignant Mesothelioma in 2023
Malignant Mesothelioma
Overview
Types of Mesothelioma
Signs and symptoms of mesothelioma
Staging of Mesothelioma
i. Staging of Malignant Pleural Mesothelioma
ii. Staging of Malignant Peritoneal Mesothelioma
Pathophysiology of Mesothelioma
Risk Factors
Diagnosis
Treatment
Treatment Algorithm
Marketed Drugs
Gemzar: Eli Lilly and Company
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Gemzar
Product Profile
Alimta: Eli Lilly and Company
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Alimta
Product Profile
Platinol: Bristol-Myers Squibb Company
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Platinol
Product Profile
Paraplatin: Bristol-Myers Squibb Company
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Paraplatin
Product Profile
Doxorubicin Hydrochloride: Pfizer
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Product Profile
Emerging Therapies
NGR-hTNF
Regulatory Milestones
Advantages & Disadvantages
Clinical Development
Product Profile
Nintedanib
Advantages & Disadvantages
Clinical Development
Product Profile
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
Global Malignant Mesothelioma: Country-Wise Market Analysis
Overview on Total Malignant Mesothelioma Market (2015)
Total Market Size of Gaucher’s Disease for 7 MM in 2013-2023
Japan
Market Size of Malignant Mesothelioma by Disease Sub-type
Drivers
Restraints
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight

Table 1: Staging of Malignant Pleural Mesothelioma, 2016
Table 2:Nintedanib, Clinical Trials by Zone, 2016
Table 3: Clinical Trials by Recruitment status, 2016
Table 4: Japan Market Size of Malignant Mesothelioma in USD, Million (2010-2023)
Table 5: Japan Malignant Mesothelioma Distribution share by sub-type in USD, Million (2015)


Figure 1: Types of Mesothelioma
Figure 2: Pathophysiology of Mesothelioma
Figure 3: Diagnositic Methods for Mesothelioma
Figure 4: Diagnostic Methods for Mesothelioma
Figure 5: Nintedanib, Clinical Trials by Zone (%), 2016
Figure 6: Total Market Size of Malignant Mesothelioma in USD, Million (2015)
Figure 19: Japan Market Size of Malignant Mesothelioma in USD, Million (2010-2023)
Figure 20: Japan Malignant Mesothelioma Distribution share by sub-type in USD, Million (2015)


★調査レポート[悪性中皮腫治療薬の日本市場:市場インサイト、疫学分析、市場予測] (コード:DLVE704009)販売に関する免責事項を必ずご確認ください。
★調査レポート[悪性中皮腫治療薬の日本市場:市場インサイト、疫学分析、市場予測]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆